skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Intercepting Radiotherapy Using a Real-Time Tumor-Tracking Radiotherapy System for Highly Selected Patients With Hepatocellular Carcinoma Unresectable With other Modalities

Journal Article · · International Journal of Radiation Oncology, Biology and Physics
 [1];  [1];  [2]; ; ; ; ;  [1];  [3]; ; ;  [1]
  1. Department of Radiology, Hokkaido University School of Medicine, Sapporo (Japan)
  2. Department of Gastroenterology, Hokkaido University School of Medicine, Sapporo (Japan)
  3. Department of General Surgery, Hokkaido University School of Medicine, Sapporo (Japan)

Purpose: To assess the clinical outcome of intercepting radiotherapy, in which radiotherapy is delivered only when a tumor in motion enters a target area, using a real-time tumor-tracking radiotherapy (RTRT) system for patients with hepatocellular carcinoma who were untreatable with other modalities because the tumors were adjacent to crucial organs or located too deep beneath the skin surface. Methods and Materials: Eighteen tumors, with a mean diameter of 36 mm, were studied in 15 patients. All tumors were treated on a hypofractionated schedule with a tight margin for setup and organ motion using a 2.0-mm fiducial marker in the liver and the RTRT system. The most commonly used dose of radiotherapy was 48 Gy in 8 fractions. Sixteen lesions were treated with a BED{sub 10} of 60 Gy or more (median, 76.8 Gy). Results: With a mean follow-up period of 20 months (range, 3-57 months), the overall survival rate was 39% at 2 years after RTRT. The 2-year local control rate was 83% for initial RTRT but was 92% after allowance for reirradiation using RTRT, with a Grade 3 transient gastric ulcer in 1 patient and Grade 3 transient increases of aspartate amino transaminase in 2 patients. Conclusions: Intercepting radiotherapy using RTRT provided effective focal high doses to liver tumors. Because the fiducial markers for RTRT need not be implanted into the tumor itself, RTRT can be applied to hepatocellular carcinoma in patients who are not candidates for other surgical or nonsurgical treatments.

OSTI ID:
21036237
Journal Information:
International Journal of Radiation Oncology, Biology and Physics, Vol. 69, Issue 2; Other Information: DOI: 10.1016/j.ijrobp.2007.03.042; PII: S0360-3016(07)00528-7; Copyright (c) 2007 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA); ISSN 0360-3016
Country of Publication:
United States
Language:
English